...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Annual Financial Reporting

"Anxious to know HL's intention. Renew or convert. Tic Toc!"

we need a lot more than hepa to renew. Can't see either happening with their guy stepping down. Still say, Zenith deal that flows money into rvx would be the best for both companies ,their shareholder's & futures. In fact it's the only thing that works imo , hepa converting at this level , disaster.

glta 

Share
New Message
Please login to post a reply